Kamel Abou Hussein, MD

Articles by Kamel Abou Hussein, MD

First-Line Treatment Regimens in Metastatic HER2+ Breast Cancer

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

November 11th 2025

Panelists discuss how evolving first-line HER2-targeted combinations are improving outcomes and redefining standards in metastatic breast cancer..

The Role of ADCs in Different Subgroups

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

November 11th 2025

Panelists discuss how ADCs are revolutionizing HER2-targeted therapy through precision delivery and improved tolerability across patient subgroups.

Clinical Trial Evidence for HER2-Targeted Therapies in Early Breast Cancer

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

November 3rd 2025

Panelists discuss how new trial data are optimizing early-stage HER2-positive breast cancer treatment through refined, evidence-based regimens.

Background Information on Targeted Therapies in Breast Cancer

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

November 3rd 2025

Panelists discuss how the evolution of HER2 testing and classification has redefined treatment strategies and expanded therapeutic opportunities in breast cancer.

Kamel Abou Hussein, MD

Articles by Kamel Abou Hussein, MD

First-Line Treatment Regimens in Metastatic HER2+ Breast Cancer

The Role of ADCs in Different Subgroups

Clinical Trial Evidence for HER2-Targeted Therapies in Early Breast Cancer

Background Information on Targeted Therapies in Breast Cancer

Trending on OncLive

Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma

FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma

Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma

Dr Carlino on 5-Year Data With Intismeran Plus Pembrolizumab in Resected Melanoma

Trastuzumab Rezetecan Elicits High ORR in HER2-High and HER2-Low Salivary Gland Carcinoma